Trastuzumab in the breast cancer treatment : efficacy and resistance mechanisms
Trastuzumab, a humanized monoclonal antibody against the HER-2 receptor, was the first targeted therapy for HER-2 positive breast cancer. The treatment of HER-2 positive breast cancer in monotherapy, but mainly in combination with cytostatics trastuzumab, showed significant efficacy and increased the time to progression/relapse and overall survival. On the other hand, despite it being administered to only a selected patient population, the response rate varies in range and duration due to the primary or acquired tumor resistance to trastuzumab. Several mechanisms contributing to the drug resistance are presumed and overcoming strategies are in development. In connection with the drug resistance there are the mechanisms of trastuzumab's action on tumor cells and the search for feasible biomarkers in order to predict the response of trastuzumab-based targeted therapies. Furthermore, we present here the actual possibilities to overcome primary or acquired trastuzumab resistance.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
2009 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti - 22(2009), 2 vom: 08., Seite 45-51 |
| Sprache: |
Slowakisch |
|---|
| Weiterer Titel: |
Trastuzumab v liecbe karcinómu prsníka: mechanizmy úcinku a rezistencie |
|---|
| Beteiligte Personen: |
Grell, P [VerfasserIn] |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 04.08.2009 Date Revised 19.11.2015 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM189249633 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM189249633 | ||
| 003 | DE-627 | ||
| 005 | 20231223183324.0 | ||
| 007 | tu | ||
| 008 | 231223s2009 xx ||||| 00| ||slo c | ||
| 028 | 5 | 2 | |a pubmed24n0631.xml |
| 035 | |a (DE-627)NLM189249633 | ||
| 035 | |a (NLM)19522373 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a slo | ||
| 100 | 1 | |a Grell, P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Trastuzumab in the breast cancer treatment |b efficacy and resistance mechanisms |
| 246 | 3 | 3 | |a Trastuzumab v liecbe karcinómu prsníka: mechanizmy úcinku a rezistencie |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 04.08.2009 | ||
| 500 | |a Date Revised 19.11.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Trastuzumab, a humanized monoclonal antibody against the HER-2 receptor, was the first targeted therapy for HER-2 positive breast cancer. The treatment of HER-2 positive breast cancer in monotherapy, but mainly in combination with cytostatics trastuzumab, showed significant efficacy and increased the time to progression/relapse and overall survival. On the other hand, despite it being administered to only a selected patient population, the response rate varies in range and duration due to the primary or acquired tumor resistance to trastuzumab. Several mechanisms contributing to the drug resistance are presumed and overcoming strategies are in development. In connection with the drug resistance there are the mechanisms of trastuzumab's action on tumor cells and the search for feasible biomarkers in order to predict the response of trastuzumab-based targeted therapies. Furthermore, we present here the actual possibilities to overcome primary or acquired trastuzumab resistance | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Trastuzumab |2 NLM | |
| 650 | 7 | |a P188ANX8CK |2 NLM | |
| 700 | 1 | |a Svoboda, M |e verfasserin |4 aut | |
| 700 | 1 | |a Simícková, M |e verfasserin |4 aut | |
| 700 | 1 | |a Fabian, P |e verfasserin |4 aut | |
| 700 | 1 | |a Vyzula, R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti |d 1998 |g 22(2009), 2 vom: 08., Seite 45-51 |w (DE-627)NLM09368763X |x 1802-5307 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2009 |g number:2 |g day:08 |g pages:45-51 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2009 |e 2 |b 08 |h 45-51 | ||